Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
D-cycloserine + glycine is a combination of two small molecules that modulate the N-methyl-D-aspartate (NMDA) receptor, specifically at the glycine modulatory site. D-cycloserine acts as a partial agonist at this site, while glycine is a full agonist. Both compounds influence NMDA receptor function, which plays a key role in synaptic plasticity and neurotransmission in the central nervous system. This combination has been investigated for its potential to enhance NMDA receptor-mediated neurotransmission and has been studied primarily in neuropsychiatric disorders such as schizophrenia, where modulation of glutamatergic signaling may improve negative symptoms[1][2][3]. D-cycloserine is also an established antibiotic used for tuberculosis but at much higher doses than those used for neuropsychiatric indications[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on d-cycloserine + glycine.